Terazosin ( DrugBank: Terazosin )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	3

6. Parkinson disease

---

Clinical trials : 2,298 /  Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05109364 (ClinicalTrials.gov)	November 23, 2021	13/10/2021	Terazosin and Parkinson's Disease Extension Study	The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study	Symptomatic Parkinson Disease;REM Sleep Behavior Disorder;Pre-motor Parkinson's Disease	Drug: Terazosin therapy	Cedars-Sinai Medical Center	NULL	Not yet recruiting	25 Years	85 Years	All	15	Phase 2	NULL
2	NCT04386317 (ClinicalTrials.gov)	November 1, 2020	24/4/2020	Terazosin Effect on Cardiac Changes in Early Parkinson's Disease	The Effect of a1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease	REM Sleep Behavior Disorder;Pre-motor Parkinson's Disease;Symptomatic Parkinson Disease	Drug: Terazosin	Cedars-Sinai Medical Center	NULL	Recruiting	25 Years	85 Years	All	15	Phase 2	United States
3	NCT03905811 (ClinicalTrials.gov)	September 24, 2019	1/4/2019	Terazosin for Parkinson's Disease	A Pilot Study of Terazosin for Parkinson's Disease	Parkinson Disease	Drug: Terazosin 5 MG;Drug: Placebo oral capsule	Jordan Schultz	University of Iowa	Completed	40 Years	90 Years	All	13	Phase 1/Phase 2	United States